Clinical test developer Renalytix received a breakthrough device designation from the FDA for its lead diagnostic KidneyIntelX.
The AI-enabled kidney disease diagnostic, the first of its kind, identifies patients with Type II diabetes with fast-progressing kidney disease.
The diagnostic uses machine-learning algorithms to evaluate predictive blood-based biomarkers, as well as a patient’s electronic health records, to detect progressive kidney disease.
